Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) reached a new 52-week high on Thursday. The stock traded as high as $19.87 and last traded at $19.8250, with a volume of 6,521 shares trading hands. The stock had previously closed at $19.82.
Analysts Set New Price Targets
Several brokerages have issued reports on SLN. Chardan Capital cut Silence Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 21st. HC Wainwright lowered shares of Silence Therapeutics from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $75.00 to $20.00 in a report on Wednesday, October 21st. William Blair downgraded shares of Silence Therapeutics from an "outperform" rating to a "hold" rating in a report on Monday, October 19th. Jefferies Financial Group lowered Silence Therapeutics from a "buy" rating to a "hold" rating and set a $20.00 price objective for the company. in a research note on Monday, October 19th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Silence Therapeutics in a research note on Thursday, October 15th. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $24.00.
Check Out Our Latest Research Report on SLN
Silence Therapeutics Price Performance
The stock has a market capitalization of $1.23 billion, a PE ratio of -18.53 and a beta of 1.34. The company's 50 day moving average price is $15.02 and its two-hundred day moving average price is $9.98.
Silence Therapeutics (NASDAQ:SLN - Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.13). Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 102.72%. Analysts forecast that Silence Therapeutics PLC Sponsored ADR will post -0.81 earnings per share for the current year.
Institutional Investors Weigh In On Silence Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. acquired a new position in Silence Therapeutics in the third quarter valued at about $26,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Silence Therapeutics by 14.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company's stock worth $93,000 after acquiring an additional 1,097 shares in the last quarter. GAMMA Investing LLC increased its holdings in Silence Therapeutics by 18.1% during the 2nd quarter. GAMMA Investing LLC now owns 11,063 shares of the company's stock worth $121,000 after purchasing an additional 1,698 shares during the period. AXQ Capital LP purchased a new stake in shares of Silence Therapeutics during the second quarter worth approximately $138,000. Finally, Bank of America Corp DE raised its holdings in shares of Silence Therapeutics by 903.8% in the 1st quarter. Bank of America Corp DE now owns 29,773 shares of the company's stock valued at $157,000 after purchasing an additional 26,807 shares in the last quarter. Hedge funds and other institutional investors own 98.73% of the company's stock.
About Silence Therapeutics
(
Get Free Report)
Silence Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce production of specific disease-related proteins. Its proprietary mRNAi GOLD platform is designed to create small interfering RNA (siRNA) medicines, including treatments that target genes expressed in the liver. The company's research and development programs have included zerlasiran, which targets lipoprotein(a), a risk factor for cardiovascular disease, and divesiran, investigated for blood disorders.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Silence Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Silence Therapeutics wasn't on the list.
While Silence Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.